In GRN-associated FTD, serum Nfl levels are elevated two–three times 2–4 years prior to the onset of clinical symptoms, enabling dynamic monitoring of neuronal axonal damage and disease progression through regular blood tests (36). This evidence concerns the gene NEFL and frontotemporal dementia.